The inhibitory effect of cannabidiol on the rewarding properties of methamphetamine in part mediates by interacting with the hippocampal D1-like dopamine receptors
- PMID: 37100273
- DOI: 10.1016/j.pnpbp.2023.110778
The inhibitory effect of cannabidiol on the rewarding properties of methamphetamine in part mediates by interacting with the hippocampal D1-like dopamine receptors
Abstract
Cannabidiol (CBD) is a potential treatment to decrease the rewarding properties of psychostimulants. However, the exact mechanism and distinct neuroanatomical areas responsible for the CBD's effects remain unclear. Indicatively, the D1-like dopamine receptors (D1R) in the hippocampus (HIP) are essential for expressing and acquiring drug-associated conditioned place preference (CPP). Therefore, given that involving D1Rs in reward-related behaviors and the encouraging results of CBD in attenuating the psychostimulant's rewarding effects, the present study sought to investigate the role of D1Rs of the hippocampal dentate gyrus (DG) in the inhibitory effects of CBD on the acquisition and expression of METH-induced CPP. To this end, over a 5-day conditioning period by METH (1 mg/kg; sc), different groups of rats were given intra-DG SCH23390 (0.25, 1, or 4 μg/0.5 μl, saline) as a D1Rs antagonist before ICV administration of CBD (10 μg/5 μl, DMSO12%). In addition, a different set of animals, after the conditioning period, received a single dose of SCH23390 (0.25, 1, or 4 μg/0.5 μl) before CBD (50 μg/5 μl) administration on the expression day. The results showed that SCH23390 (1 and 4 μg) significantly reduced the suppressive effects of CBD on the acquisition of METH place preference (P < 0.05 and P < 0.001, respectively). Furthermore, the highest dose of SCH23390 (4 μg) in the expression phase remarkably abolished the preventive effects of CBD on the expression of METH-seeking behavior (P < 0.001). In conclusion, the current study revealed that CBD's inhibitory effect on rewarding properties of METH partially acts through D1Rs in the DG area of the HIP.
Keywords: Cannabidiol; D1-like dopamine receptor; Dentate gyrus; Hippocampus; Methamphetamine; Reward.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors have no conflict of interest in this article.
Similar articles
-
Involvement of Hippocampal D1-Like Dopamine Receptors in the Inhibitory Effect of Cannabidiol on Acquisition and Expression of Methamphetamine-Induced Conditioned Place Preference.Neurochem Res. 2021 Aug;46(8):2008-2018. doi: 10.1007/s11064-021-03350-w. Epub 2021 May 15. Neurochem Res. 2021. PMID: 33993443
-
Hippocampal D1-like dopamine receptor as a novel target for the effect of cannabidiol on extinction and reinstatement of methamphetamine-induced CPP.Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jul 13;133:111025. doi: 10.1016/j.pnpbp.2024.111025. Epub 2024 May 8. Prog Neuropsychopharmacol Biol Psychiatry. 2024. PMID: 38729234
-
The role of D1-like dopamine receptors within the ventral tegmental area in the cannabidiol's inhibitory effects on the methamphetamine-induced conditioned place preference in rats.Brain Res Bull. 2024 Oct 1;216:111038. doi: 10.1016/j.brainresbull.2024.111038. Epub 2024 Aug 3. Brain Res Bull. 2024. PMID: 39097033
-
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.Molecules. 2019 Jul 16;24(14):2583. doi: 10.3390/molecules24142583. Molecules. 2019. PMID: 31315244 Free PMC article. Review.
-
Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.Iran J Pharm Res. 2021 Fall;20(4):152-164. doi: 10.22037/ijpr.2021.114918.15106. Iran J Pharm Res. 2021. PMID: 35194436 Free PMC article. Review.
Cited by
-
Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacol Biochem Behav. 2025 Mar;248:173952. doi: 10.1016/j.pbb.2024.173952. Epub 2024 Dec 22. Pharmacol Biochem Behav. 2025. PMID: 39719161 Free PMC article. Review.
-
Identification of the circRNA-miRNA-mRNA network for treating methamphetamine-induced relapse and behavioral sensitization with cannabidiol.CNS Neurosci Ther. 2024 May;30(5):e14737. doi: 10.1111/cns.14737. CNS Neurosci Ther. 2024. PMID: 38702929 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical